The partnership between Aparito and the University of Birmingham is an exciting opportunity to create innovative remote patient monitoring solutions across a variety of disease areas including one of our Success Stories, ePROs and eConsent for Treatment & Understanding of Long COVID (TLC).
This partnership will see the configuration of Aparito’s flagship software platform Atom5™ to assess patient quality of life and symptoms in clinical trials and routine NHS care. The partnership brings together international experts in patient-reported outcomes methodology, input from patients and clinicians, with cutting-edge and innovative technology.
The aim of the partnership is to co-develop multiple digital Patient-Reported Outcomes (PROs) for use in a wide range of disease groups to assess treatment safety and effectiveness from the patient perspective and enhance the patient experience of clinical trials and routine care. These data will support patient care and provide evidence to inform regulators and policymakers such as the Medicines and Healthcare Regulatory Agency (MHRA) and the National Institute for Health (NICE).
Working with the team at the University of Birmingham to provide a technology solution for PRiORiTy has highlighted how deeply clinicians care about the patient experience and how they can improve treatment within the patient cohort.
Having such an approachable and knowledgeable team has allowed the University of Birmingham to detail very specifically how we can adapt our Aparito Atom5™ technology to really change a patient’s life and we cannot wait to work with the team again on future projects.
Would you like to partner with us? Contact us using the form below.